Literature DB >> 25973324

Buprenorphine treatment for narcotic addiction: not without risks.

Randy A Sansone1, Lori A Sansone1.   

Abstract

While most clinicians will never prescribe buprenorphine or combined buprenorphine/naloxone, familiarity with the risks of these pharmacological approaches to the treatment of narcotic addiction remains relevant. Overall, medication-assisted treatment has clearly resulted in meaningful gains for a number of individuals who are addicted to narcotics (i.e., opiates and opioids). However, a certain level of risk is inherent with these approaches. For example, both buprenorphine and buprenorphine/naloxone may be diverted and misused (e.g., intravenously injected, intranasally administered), particularly buprenorphine. Likewise, when illicitly injected, both can cause infectious complications as well as result in death from overdose. The risk of death with buprenorphine overdose appears to be heightened with the coadministration of either benzodiazepines or sedative/hypnotics. To conclude, as with all interventions in medicine, buprenorphine treatment for narcotic addiction has a clinically fluctuating risk/benefit equation that must be continually monitored.

Entities:  

Keywords:  Buprenorphine; buprenorphine/naloxone; naloxone; narcotics; opiate addiction; opiates; opioid addiction; opioids

Year:  2015        PMID: 25973324      PMCID: PMC4420168     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  39 in total

1.  [Monitoring of the misuse of prescription drugs by clients of outpatient addiction treatment centres (PHAR-MON, formerly: Ebis-med). Monitoring of medication misuse].

Authors:  H Küfner; S Rösner
Journal:  Gesundheitswesen       Date:  2008-05

Review 2.  Misuse of medicines in the European Union: a systematic review of the literature.

Authors:  Alicia Casati; Roumen Sedefov; Tim Pfeiffer-Gerschel
Journal:  Eur Addict Res       Date:  2012-05-04       Impact factor: 3.015

3.  Six deaths linked to misuse of buprenorphine-benzodiazepine combinations.

Authors:  M Reynaud; A Tracqui; G Petit; D Potard; P Courty
Journal:  Am J Psychiatry       Date:  1998-03       Impact factor: 18.112

4.  Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France.

Authors:  V Pauly; V Pradel; L Pourcel; S Nordmann; E Frauger; M Lapeyre-Mestre; J Micallef; X Thirion
Journal:  Drug Alcohol Depend       Date:  2012-04-03       Impact factor: 4.492

5.  Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.

Authors:  Raminta Daniulaityte; Russel Falck; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2011-10-28       Impact factor: 4.492

6.  Post-marketing surveillance of methadone and buprenorphine in the United States.

Authors:  Nabarun Dasgupta; Elise J Bailey; Theodore Cicero; James Inciardi; Mark Parrino; Andrew Rosenblum; Richard C Dart
Journal:  Pain Med       Date:  2010-06-08       Impact factor: 3.750

7.  Buprenorphine replacement therapy: a confirmed benefit.

Authors: 
Journal:  Prescrire Int       Date:  2006-04

8.  Buprenorphine for opioid dependence.

Authors:  Walter Ling
Journal:  Expert Rev Neurother       Date:  2009-05       Impact factor: 4.618

9.  Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland.

Authors:  Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Kevin E O'Grady; Robert P Schwartz
Journal:  Am J Addict       Date:  2009 Sep-Oct

10.  Six deaths linked to concomitant use of buprenorphine and benzodiazepines.

Authors:  M Reynaud; G Petit; D Potard; P Courty
Journal:  Addiction       Date:  1998-09       Impact factor: 6.526

View more
  8 in total

1.  Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D.

Authors:  Walid F Gellad; Xinhua Zhao; Carolyn T Thorpe; Joshua M Thorpe; Florentina E Sileanu; John P Cashy; Maria Mor; Jennifer A Hale; Thomas Radomski; Leslie R M Hausmann; Michael J Fine; Chester B Good
Journal:  Subst Abus       Date:  2016-12-07       Impact factor: 3.716

2.  Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.

Authors:  Zoe M Weinstein; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong Kim; Gabriela Gryczynski; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2016-11-05       Impact factor: 4.492

3.  Use and Misuse of Opioids in Maine: Results From Pharmacists, the Prescription Monitoring, and the Diversion Alert Programs.

Authors:  Brian J Piper; Clare E Desrosiers; John W Lipovsky; Matthew A Rodney; Robert P Baker; Kenneth L McCall; Stephanie D Nichols; Sarah L Martin
Journal:  J Stud Alcohol Drugs       Date:  2016-07       Impact factor: 2.582

4.  Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.

Authors:  Kirsten E Smith; Martha D Tillson; Michele Staton; Erin M Winston
Journal:  Drug Alcohol Depend       Date:  2020-01-09       Impact factor: 4.492

5.  Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis.

Authors:  Kevin Y Xu; Jacob T Borodovsky; Ned Presnall; Carrie M Mintz; Sarah M Hartz; Laura J Bierut; Richard A Grucza
Journal:  Am J Psychiatry       Date:  2021-03-03       Impact factor: 19.242

6.  Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers.

Authors:  Laura G Duncan; Sonia Mendoza; Helena Hansen
Journal:  J Addict Med Ther Sci       Date:  2015-08-03

7.  Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions.

Authors:  Abhishek Ghosh; Debasish Basu; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2018 Jul-Sep       Impact factor: 1.759

Review 8.  Emerging Evidence for Cannabis' Role in Opioid Use Disorder.

Authors:  Beth Wiese; Adrianne R Wilson-Poe
Journal:  Cannabis Cannabinoid Res       Date:  2018-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.